Drug intelligence / Profile preview

SNAPduo 101

Development stage: Preclinical
Lead developer: Black Canyon Bio
Modality: Peptides, Vaccines & Immunotherapeutics

Overview

SNAPduo 101 is an individualized peptide cancer vaccine being developed by Black Canyon Bio for the treatment of virus-associated cancers. Utilizing the proprietary SNAP (Specific Neo-Antigen Peptides) Technology platform, the vaccine is designed to target specific neoantigens present on a patient's tumor cells. By delivering these peptide neoantigens, SNAPduo 101 aims to prime and activate the patient's immune system to recognize and eliminate cancer cells. The program is currently in the IND-enabling stage of development, with clinical trials projected to begin in 2026.

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on SNAPduo 101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SNAPduo 101.

Explore the full profile